

ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

SYMPOSIUM ATP1A3 IN DISEASE

FROM GENE MUTATIONS TO NEW TREATMENTS

Brussels, Belgium, 10 - 11 December 2012

Organizers

European Network for Research on Alternating Hemiplegia & Duke University

Program Committee

Chairs: David Goldstein, Duke University, United States

Tsveta Schyns, ENRAH, Belgium

Alexis Arzimanoglou University Hospitals of Lyon, France
Allison Brashear Wake Forest University, NC, United States
Knut Brockmann Georg August University, Göttingen, Germany

Steven Clapcote University of Leeds, United Kingdom Kathleen Freson Catholic University of Leuven, Belgium

Erin Heinzen Duke University, United States

Kamran Khodakhah Albert Einstein College of Medicine, United States

Mohamed Mikati Duke University, United States

Brian Neville University College London, United Kingdom

Poul Nissen Aarhus University, Denmark

Laurie Ozelius Mount Sinai School of Medicine, NY, United States

Bente Vilsen Aarhus University, Denmark

Arn v/d Maagdenberg Leiden University Medical Centre, the Netherlands

Registration

To participate in the Symposium, please, complete the Participant registration Form.

Deadline for registration is 1st December 2012.

Venue

Basil & Co Brussels Louise Seminar, Avenue Louise 156, 1050, Brussels, Belgium

Venue Map.



ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

PROGRAM

Monday, December 10th, 2012

Opening Session Chairs: Tsveta Schyns and David Goldstein		
10:00 10:30-10:45 10:45-10:55	Registration Opens Welcome Family Foundations involvement for AHC international research	Tsveta Schyns Dominique Poncelin
11:55-11:05	The parents perspective	Sigurður Hólmar Jóhannesson
11:05 -11:35	Genetics of rare disease, application of NGS in clinical care	David Goldstein
	Introduction to Alternating Hemiplegia of Child	lhood
11:35-11:55	Chair: Brian Neville Overview of AHC	Mohamad Mikati
11.33-11.33	Overview of AHC	MONAMAU MIKALI
15:55-12:10	Is AHC a progressive disease?	Brian Neville
12:10-12:20	Discussion	
12:20-13:00	Lunch	
	AHC Genetics	
	Chair: Giovanni Neri	
13:00-13:15	ATP1A3 and AHC: The Nature Genetics research group	Erin Heinzen
13:15-13:30	Identifying the gene associated with AHC: the Lancet Neurology research group	Hendrik Rosewich
13:30-13:45	ATP1A3 mutations in sporadic cases from the I.B.AHC Biobank and Clinical Registry	Fiorella Gurrieri
13:45-14:00	ATP1A3 mutations in sporadic and familial AHC cases from the Utah registry	Sandra P. Reyna
14:00-14:15	Identification of ATP1A3 mutations by exome sequencing as the cause of AHC in Japanese patients	Atsushi Ishii
14:15-14:30	Phenotypic analysis of AHC patients with ATP1A3 mutations: Preliminary results.	Eleni Panagiotakaki
14:30-14:45	Identifying fields for future clinical research in AHC	Alexis Arzimanoglou



SYMPOSIUM ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

Roundtable Discussion Clinical genetic correlations and search for new genes for AHC

Moderators: Arn V.D. Maagdenberg and Alexis Arzimanoglou

14:45-15:45

- Key challenges
- · Directions moving forward
- Collaborative groupings
- Active support and collaboration to researchers in the field of AHC and related diseases - Filippo Franchini

15:45- 16:00 Break/Refreshments

	Rapid-Onset Dystonia-Parkinsonism Chair: <i>Mohamad Mikati</i>	
16:00-16:20	AHC versus Rapid-Onset Dystonia-Parkinsonism: allelic disorders and a phenotypic spectrum	Knut Brockmann
16:20-16:40	Expanded RDP phenotype: motor and non-motor features	Allison Brashear
16:40-17:00	Dystonia phenotype, circuitry, and, physiology	Mark Edwards
17:00-17:20	Cerebellar dysfunction in RDP	Kamran Khodakhah
17:20-17:40	Imaging in Dystonia in general	Kristina Simonyan
17:40-18:00	The genetics of Dystonia	Laurie J. Ozelius
18:00-19:00	Discussion and Refreshments	
19:00-22:00	Dinner	
	Dinner talk From genetics to therapy: The story of neonatal diabetes	Frances Ashcroft



SYMPOSIUM ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

Tuesday December 11th, 2012

Functional Studies of the Na/K ATPase – Structure/Function Chair: David Goldstein		
9:00-9:20	Genes and transgenic models in migraine: Lessons for AHC?	Arn V.D. Maagdenberg
9:20-9:40	Structure, function, and biological roles of Na, K-ATPase isoforms in excitable tissues	Kathy Sweadner
9:40-10:00	Insights to disease mechanisms from structural studies of Na+, K+-ATPase and related ion pumps	Poul Nissen
10:00-10:20	Functional consequences of alpha-3 Na, K-ATPase mutations at the molecular and cellular levels	Bente Vilsen
10:20-10:40	Cell biological and mutational studies of Na, K-ATPase, insect cell expression system	Jan Koenderink
11:40-11:00	Functional and proteomic studies in platelets from AHC patients reveals a lysosomal granule defect	Michela Di Michele
11:00-11:20	Coffee and refreshments	

Functional Studies of the Na/K ATPase .Electro Physiology & in vivo work Chair: Sophie Nicole				
11:20-11:40	Electrophysiological studies in oocytes of disease mutations in atp1a2 and 3.	Thomas Friedrich		
11:40-12:00	Electrophysiological studies in oocytes of Na, K-ATPase mechanisms	Hanne Poulsen		
12:00-12:20	Electrophysiology of Na, K-ATPase	David Gadsby		
12:20-13:30	Lunch break			



ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

13:30-13:50	A Mouse Model for ATP1A3-related Alternating Hemiplegia of Childhood	Steven Clapcote
13:50-14:10	Increased Susceptibility to Cortical Spreading Depression in the Mouse Model of Familial Hemiplegic Migraine Type 2	Giorgio Casari
14:10-14:30	Zebrafish and mouse models of atp1a2 and atp1a3	Karin Lykke-Hartmann
14:30-14:50	Mania-like behaviour induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase α3 sodium pump	Greer S. Kirshenbaum

Roundtable Discussion Functional Biology of ATP1A3 and ATP1A3 Mutations

Moderators: Poul Nissen and Bente Vilsen

14:50-15:30

- Key challenges
- Directions moving forward
- Collaborative groupings

Roundtable Discussion Collaborations and Funding

Moderators: Tsveta Schyns and David Goldstein

15:30-16:20

- Key challenges
- Directions moving forward
- Collaborative groupings
- Outcomes of the Symposium

16:20-16:30 Closing message from the AHC Community - Jeff Wuchich

16:30 End of the meeting



ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

Speakers and Chairs

Alexis Arzimanoglou

Associated Professor of Neurology and Child Neurology, University Children's Hospital of Lyon, France

Frances Ashcroft

The Royal Society GlaxoSmithKline Research Professor University Laboratory of Physiology Oxford and Fellow of Trinity College, Oxford University, United Kingdom

Allison Brashear

Professor and Chair of Neurology Wake Forest University School of Medicine, United States

Knut Brockmann

Professor of Paediatrics and Child Neurology, Georg August University Göttingen, Germany

Giorgio Casari

Neurogenomics Unit Center for Genomics & Bioinformatics San Raffaele University School of Medicine, Italy

Steven Clapcote

Lecturer in Pharmacology, University of Leeds United Kin15:30-16:20gdom

Mark Edwards

Senior Lecturer, University College London, Institute of Neurology, London United Kingdom

Filippo Franchini

I.B.AHC Project Manager Board of Advisors of A.I.S.EA Italy

Thomas Friedrich

Professor, Institute of Chemistry Technical University of Berlin Germany

David Gadsby

Professor Laboratory of Cardiac and Membrane Physiology Rockefeller University, United States

David B. Goldstein

Professor & Director Center for Human Genome Variation Duke University United States

Fiorella Gurrieri

Institute of Medical Genetics Università Cattolica del Sacro Cuore Rome, Italy

Erin Heinzen

Assistant Research Professor Center for Human Genome Variation Duke University United States

Atsushi Ishii

Department of Pediatrics School of Medicine, Fukuoka University Japan

Sigurður Hólmar Jóhannesson

President of AHC Iceland Board member of ENRAH Iceland

Kamran Khodakhah

Professor Dominick P. Purpura Department of Neuroscience Albert Einstein College of Medicine United States



ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

Greer S. Kirshenbaum

Postdoctoral Research Scientist University of Columbia Canada

Jan Koenderink

Associate Professor Nijmegen Centre for Molecular Life Sciences The Netherlands

Michela Di Michele

PostDoc Katolieke Universiteit Leuven Belgium

Karin Lykke-Hartmann

Associate Professor Department of Biomedicine Aarhus University, Denmark

Mohamad Mikati

Professor of Paediatrics & Neurobiology Duke University United States

Giovanni Neri

Professor of Medical Genetics & Director of the Institute of Medical Genetics Università Cattolica del S Cuore Rome, Italy

Brian Neville

Emeritus Professor of Childhood Epilepsy UCL Institute of Child Health United Kingdom

Sophie Nicole

Institut du cerveau et de la moëlle épinière INSERM UMR 975, Université Paris 6 Pierre et Marie Curie, France

Poul Nissen

Professor
Department of Molecular Biology and
Genetics, Aarhus University
Denmark

Laurie J. Ozelius

Associate Professor Genetics and Genomic Sciences & Neurology Mount Sinai Hospital, United States

Eleni Panagiotakaki

Hôpital Femme Mere Enfant Hospices Civils de Lyon France

Dominique Poncelin

President of Association Française de l'Hémiplégie Alternante, AFHA France

Hanne Poulsen

Department of Molecular Biology and Genetics, Aarhus University, Denmark

Sandra P. Reyna

Assistant Professor Paediatric Motor Disorders Research Program, University of Utah School of Medicine, United States

Hendrik Rosewich

Department of Paediatrics and Adolescent Medicine, Georg August University Göttingen, Germany

Tsveta Schyns-Liharska

Consultant Research Management Founder and Board Member of ENRAH Brussels, Belgium

EUROPEAN NETWORK FOR RESEARCH ON ALTERNATING HEMIPLEGIA

SYMPOSIUM

ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

Kristina Simonyan

Assistant Professor Neurology & Otolaryngology Mount Sinai Hospital United States

Kathy Sweadner

Associate Professor Molecular Neurophysiology, Massachusetts General Hospital, United States

Arn Van den Maagdenberg

Professor of Genetics Leiden University Medical Centre The Netherlands

Bente Vilsen

Professor Department of Biomedicine Aarhus University, Denmark

Jeff Wuchich

President of the AHC Foundation, United States



ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

PARTICIPANT REGISTRATION FORM

Symposium ATP1A3 in disease 10 - 11 December 2012, Basil & Co Brussels Louise, Belgium

Please, use CAPITAL LETTERS or TYPE and return this form latest 1 December 2012 to:

ENRAH Brussels Office,

Email: ts@enrah.net Tel. +32 2 325 86 94

Registration Details Dr. ☐ Mr. ☐ Ms. ☐ Prof. Family Name: -----First Name: ------Position: -----Department: -----Organisation/Company: ------Town: ----- Country: -----Zip code: -----Phone: -----Email: -----O Specific diet requirements (vegetarian, allergies ...): ------**Registration Fee** The registration fee covers the Symposium brochure, coffee breaks and lunches, and dinner on Monday 10 December Standard € 500.00 Reduced Registration Fee * € 300.00 * For Health professionals and non-profit organisations registered before 10 November 2012 **Method of Payment:** Bank transfer to: ENRAH, Bank: Easybank AG, Quellenstraße 51-55, A-1100 Vienna, Austria IBAN: AT511420020010398003 BIC: EASYATW1. **Billing Information** (if different from above): **Cancellation Policy**

All cancellations must be in writing. Cancellations received before 1 December 2012 are subject to a charge of 25% of the registration fees for reservation costs. After 1 December 2012 full payment will be requested and refunds will not be provided. Transfer of the registration to other persons is at no extra cost.

Privacy

By filling out the registration form, the participant gives consent that ENRAH can process the data provided within the framework of the Symposium This includes, all handling needed for the applicant's participation at the event and for the drafting of a list of participants which will be distributed at the Symposium.

Important

Written confirmation will be sent after the payment has been received. If you have not received your confirmation within five working days, please contact the ENRAH office.



ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS




Brussels, Belgium, 10 - 11 December 2012

VENUE MAP

Basil & Co Brussels Louise, Avenue Louise 156, 1050 Brussels



brussels louise





ATP1A3 IN DISEASE FROM GENE MUTATIONS TO NEW TREATMENTS



Brussels, Belgium, 10 - 11 December 2012

SPONSORS



ENRAH

European Network for Research on Alternating Hemiplegia www.enrah.net




RTD Services

Research and Technological Development and innovation projects www.rtd-services.com



AFHA

French Association for Alternating Hemiplegia www.afha.org



AHCAI

Icelandic Association for Alternating Hemiplegia www.ahc.is



A.I.S.EA Onlus

Italian Association for Alternating Hemiplegia www.aisea.org



AESHA

Spanish Association for Alternating Hemiplegia www.aesha.org



AHC Vereniging Nederland

Dutch Association for Alternating Hemiplegia

www.ahckids.nl



AHC-Deutschland e.V.

German Association for Alternating Hemiplegia

www.ahckids.de



AHCF

US Foundation for Alternating Hemiplegia

www.ahckids.org